# OnCo record proud-pv (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/proud-pv/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "proud-pv", "NCT01949805" ;
  schema:name "PROUD-PV and CONTINUATION-PV"@en ;
  schema:description "PROUD-PV and its extension showed that ropeginterferon matches hydroxyurea in the first year and then pulls ahead, with more complete responses and far more molecular responses by three years."@en ;
  schema:url <https://onco.cc/trials/proud-pv/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01949805>, <https://clinicaltrials.gov/study/NCT02218047>, <https://doi.org/10.1016/S2352-3026(19)30236-4> ;
  onco:status "positive" ;
  onco:tag "polycythaemia-vera", "mpn" ;
  onco:phase "3" ;
  schema:startDate "2013-09" ;
  onco:cancers <https://onco.cc/cancers/polycythaemia-vera/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/ropeginterferon-alfa-2b/>, <https://onco.cc/drugs/hydroxyurea/> ;
  onco:companies <https://onco.cc/companies/pharmaessentia/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-gisslinger-lancet-haematol/> .